Selinexor Granted Fast Track Designation for Myelofibrosis
In the United States, the FDA grants Fast Track designation to drugs that treat rare and serious conditions or fill unmet needs. The designation helps to facilitate and expedite the…
In the United States, the FDA grants Fast Track designation to drugs that treat rare and serious conditions or fill unmet needs. The designation helps to facilitate and expedite the…
Karyopharm is currently developing selinexor, an investigational treatment for recurrent or advanced endometrial cancer. They had planned to submit a supplemental New Drug Application (sNDA) to the FDA, but now…